Warning: The NCBI web site requires JavaScript to function. more...
Department of Pediatrics, University of California, San Diego, CA, USA. chchambers@ucsd.edu
For female patients with rheumatoid arthritis, the availability of a host of new disease modifying antirheumatic drugs has raised important questions about fetal safety if a woman becomes pregnant while she is being treated. In addition, there is limited safety information regarding many of the older medications commonly used to treat rheumatoid arthritis in women of reproductive age. Current summary pregnancy risk information for selected medications used to treat rheumatoid arthritis is reviewed in the context of the pregnancy label category. In addition, the strengths and weaknesses of post-marketing strategies for developing new pregnancy safety information are described.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on